Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 14/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9404421 | 0.86 | CHRM1 (0.33) | CHRM1CHRM4CHRM5GRM5HTT | |
| SCHEMBL7817015 | 0.72 | CHRM1 (0.31) | CHRM1KCNK3KCNK9 | |
| SCHEMBL13045376 | 0.71 | ALDH1A1 (0.40) | CHRM1POLBGAA | |
| SCHEMBL9404504 | 0.70 | CPT1A (0.36) | CHRM1LMNAMAPTPOLBGAA | |
| SCHEMBL1016674 | 0.70 | CHRM1 (0.42) | CHRM1CHRM4CHRM5GRM5GAA | |
| SCHEMBL15618675 | 0.70 | CHRM1 (0.42) | CHRM1CHRM4CHRM5GRM5GAA | |
| SCHEMBL11360559 | 0.69 | CHRM1 (0.36) | CHRM1CHRM4CHRM5GRM5KCNK3 | |
| SCHEMBL8217742 | 0.68 | MAPT (0.33) | CHRM1CHRM4CHRM5GRM5MAPT | |
| SCHEMBL884784 | 0.68 | CHRM1 (0.42) | CHRM1CHRM4CHRM5GRM5LMNA | |
| SCHEMBL3745563 | 0.67 | MAPK1 (0.48) | CHRM1CHRM4CHRM5GRM5POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6281233-B1 | AZABICYCLIC RING-SUBSTITUTED THIA- OR OXADIAZOLES | NOVO NORDISK A/S (DK) | 2001-08-28 | — | — | US | disclosed |
| US-6281232-B1 | AZABICYCLIC RING-SUBSTITUTED THIA- OR OXADIAZOLES | NOVO NORDISK A/S (DK) | 2001-08-28 | — | — | US | disclosed |
| US-6271229-B1 | ADMINISTERING A 1,2,5-OXADIAZOLE COMPOUND OR 1,2,5-THIADIAZOLE COMPOUND | NOVO NORDISK A/S (DK) | 2001-08-07 | — | — | US | disclosed |
| US-6265419-B1 | IRRITABLE BOWEL DISORDER | NOVO NORDISK A/S (DK) | 2001-07-24 | — | — | US | disclosed |
| US-6265418-B1 | ANTICOAGULANTS | UBE INDUSTRIES, LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| EP-0714394-B1 | ANTIPSYCHOTIC METHOD WITH THIADIAZOLE AND OXADIAZOLE DERIVATIVES | NOVO NORDISK AS (DK) | 2001-06-20 | — | — | EP | disclosed |
| EP-1020467-A1 | N-ACYLAMINO ACID AMIDE COMPOUNDS AND INTERMEDIATES FOR PREPARATION THEREOF | UBE INDUSTRIES LIMITED (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-5968926-A | SCHIZOPHRENIA TREATMENT WITH 1,2,5-OXADIAZOLE OR 1,2,5-THIADIAZOLE | NOVO NORDISK A/S (DK) | 1999-10-19 | — | — | US | disclosed |
| EP-0544779-B1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 1998-12-02 | — | — | EP | disclosed |
| US-5663182-A | ADMINISTERING AN AZABICYCLIC RING SUBSTITUTED THIADIAZOLE OR OXADIAZOLE TO A MAMMAL | BYMASTER FRANKLIN PORTER (US) | 1997-09-02 | — | — | US | disclosed |
| US-5574043-A | ALZHEIMERS, GLAUCOMA, ANALGESIC | NOVO NORDISK A/S (DK) | 1996-11-12 | — | — | US | disclosed |
| EP-0735869-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1996-10-09 | — | — | EP | disclosed |
| US-5527813-A | THERAPEUTICALLY ACTIVE AZABICYCLIC COMPOUNDS USEFUL AS STIMULANTS OF THE COGNITIVE FUNCTION OF THE FOREBRAIN AND IN THE TREATMENT OF ALZHEIMER'S DISEASE | NOVO NORDISK A/S (DK) | 1996-06-18 | — | — | US | disclosed |
| EP-0714394-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1996-06-05 | — | — | EP | disclosed |
| WO-1996014316-A1 | A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS | NOVO NORDISK A/S (DK) | 1996-05-17 | — | — | WO | disclosed |
| WO-1995017180-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1995-06-29 | — | — | WO | disclosed |
| WO-1995005379-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1995-02-23 | — | — | WO | disclosed |
| US-5260314-A | Cognition activators, glaucoma analgesic | NOVO NORDISK A/S (DK) | 1993-11-09 | — | — | US | disclosed |
| EP-0544779-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1993-06-09 | — | — | EP | disclosed |
| WO-1992003433-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1992-03-05 | — | — | WO | disclosed |